Finland's Tamro Corp and Norwegian pharmacy chain Apokjeden SA haveagreed to integrate the former's Norwegian Tamro Distribution unit into the latter. Tamro will sell its majority share in Tamro Distribution to Apokjeden, which in turn will issue a private placement to Tamro.
Tamro's ownership of Apokjeden will rise to 49%. As a net result of the transactions, Tamro will strengthen Apokjeden's capital structure by 220 million Norwegian kroner ($25.2 million). At present, Apokjeden covers nearly 40% of pharmacy sales in Norway which, added to Tamro Distribution's 30% market share, will make it a formidable force.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze